Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NSAIDs vs Remsima in axial spondyloarthritis
2024-513213-13-00Phase 4Authorised
- Sponsor
- St. Elisabeth Gruppe
- Start
- Dec 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of infliximab in axial spondyloarthritis (axSpA) (2 arms), sponsored by St. Elisabeth Gruppe. Primary endpoint: ASDAS low disease activity at 12 weeks. Planned start Dec 2024; status: authorised.
02
Drugs
infliximab
03
Conditions
axial spondyloarthritis (axSpA)
Beyond the preview
Go deeper on 2024-513213-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513213-13-00.